Form 4: Novavax Director Rachel K. King Sells 4,150 Shares
SEC Form 4 Filing
Director Rachel K. King sold 4,150 shares of Novavax Inc. (NVAX) on December 13, 2024, at a price of $9.0205 per share.
Summary
- On December 13, 2024, Rachel K. King, a director of Novavax Inc. (NVAX), sold 4,150 shares of common stock.
- The transaction was executed at a price of $9.0205 per share.
- Following the sale, Rachel K. King directly owns 14,770 shares of Novavax common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a transaction by an insider. It doesn't inherently convey positive or negative sentiment, but the sale of shares could be interpreted neutrally or slightly negatively depending on the context.
Industry Context
Insider sales are a common occurrence and are publicly disclosed to ensure transparency in the market. The sale by a director may be for personal financial planning reasons and does not necessarily indicate a negative outlook on the company.
Stakeholder Impact
- The sale of shares by a director could have a minor impact on shareholder confidence, although such transactions are common and often related to personal financial planning.
Key Dates
| Date | Description |
|---|---|
| 12/13/2024 | Date of transaction: Rachel K. King sold 4,150 shares of Novavax stock. |
| 12/16/2024 | Date of signature: Form 4 signed by Mark J. Casey, Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.